Suppr超能文献

肿瘤浸润淋巴细胞在肝细胞癌中的预后价值:系统评价和荟萃分析。

The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis.

机构信息

Department of Biliary and Pancreatic Surgery/Cancer Research Center Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.

Department of Hepatobiliary and Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China.

出版信息

Sci Rep. 2017 Aug 8;7(1):7525. doi: 10.1038/s41598-017-08128-1.

Abstract

Previous clinical studies have found that the levels of tumor-infiltrating lymphocytes (TILs) significantly correlated with prognosis in hepatocellular carcinoma (HCC). However, these conclusions and data remain controversial. We performed a systematic review and meta-analysis to assess the prognostic value and clinical utilization of TILs in patients with HCC. A total of 23 relevant studies of 3173 patients were included into our meta-analysis. The results demonstrated that high levels of CD8 and CD3 TILs had a better prognostic value on overall survival (OS), with HRs of 0.71 (P = 0.04) and 0.63 (P = 0.03), respectively, compared to low levels, as did high levels of CD8 , CD3 and CD4 TILs on disease/recurrence-free survival (DFS/RFS), with HRs of 0.66 (P = 0.01), 0.60 (P = 0.01) and 0.79 (P = 0.04), respectively. In contrast, high levels of FoxP3 TILs had a worse prognostic value on OS and DFS/RFS, with HRs of 2.06 (P < 0.00001) and 1.77 (P < 0.00001), respectively. The FoxP3/CD4 and FoxP3/CD8 ratios negatively correlated with OS and DFS/RFS. These findings suggest that TILs may serve as a prognostic biomarker in HCC. However, further research should be performed to clarify the clinical value of TILs in HCC.

摘要

先前的临床研究发现,肿瘤浸润淋巴细胞(TILs)的水平与肝细胞癌(HCC)的预后显著相关。然而,这些结论和数据仍然存在争议。我们进行了系统的综述和荟萃分析,以评估 TILs 在 HCC 患者中的预后价值和临床应用。共有 23 项涉及 3173 名患者的相关研究被纳入我们的荟萃分析。结果表明,高水平的 CD8 和 CD3 TILs 对总生存期(OS)具有更好的预后价值,与低水平相比,风险比(HR)分别为 0.71(P=0.04)和 0.63(P=0.03),高水平的 CD8 、CD3 和 CD4 TILs 对疾病/复发无进展生存期(DFS/RFS)也具有更好的预后价值,HR 分别为 0.66(P=0.01)、0.60(P=0.01)和 0.79(P=0.04)。相比之下,高水平的 FoxP3 TILs 对 OS 和 DFS/RFS 具有更差的预后价值,HR 分别为 2.06(P<0.00001)和 1.77(P<0.00001)。FoxP3/CD4 和 FoxP3/CD8 比值与 OS 和 DFS/RFS 呈负相关。这些发现表明 TILs 可能作为 HCC 的预后生物标志物。然而,需要进一步的研究来阐明 TILs 在 HCC 中的临床价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd69/5548736/d4e695ff9304/41598_2017_8128_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验